Alzheimer's disease: major drug trial results to watch in 2022 and beyond

Three Phase III trials in Alzheimer’s disease eye a different fate than Biogen’s Aduhelm, while another key study targets a novel mechanism.

Related Keywords

Dennis Selkoe ,George Perry ,Eli Lilly ,Contract Manufacturing Organisation ,Time Data Services For Clinical Research ,Like Aduhelm ,Clinical Trials Arena ,Neurological Diseases ,San Antonio ,Clinical Dementia Rating ,Alzheimer Disease Assessment Scale Cognition ,Daily Living ,Disease Rating Scale ,Time Data Services ,Clinical Research ,Manufacturing Organisation ,Pharmaceutical Supply ,Regulatory Consultation ,